PMID- 17008023
OWN - NLM
STAT- MEDLINE
DCOM- 20070404
LR  - 20151119
IS  - 0306-9877 (Print)
IS  - 0306-9877 (Linking)
VI  - 68
IP  - 2
DP  - 2007
TI  - Neurotrophic receptor TrkB: Is it a predictor of poor prognosis for carcinoma 
      patients?
PG  - 407-9
AB  - The neurotrophic receptor tyrosine kinase TrkB, while binding its high affinity 
      ligand brain-derived neurotrophic factor (BDNF), will play an essential role for 
      nervous system development, neuronal survival, differentiation, and maintenance. 
      However, accumulating evidences implies that TrkB signal pathway may also be 
      involved in a variety of human cancers, in which TrkB is likely to play a role in 
      initiation and metastasis of carcinomas. Overexpression of TrkB is often 
      correlated with the tumorigenesis, angiogenesis and drug resistance in these 
      malignancies, contributing significantly to the metastasis and aggressive 
      phenotype of these poor prognosis tumors. The evidences to show the significant 
      contribution of TrkB to malignancy not only came from solid tumors such as 
      neoblastoma, pancreas cancer, Wilm's tumor and hepatocarcinoma, but also came 
      from haematological malignancies such as Hodgkin lymphoma and multiple myeloma. 
      In summary, besides its role in development and function of nervous system, TrkB 
      is likely to also play a role in initiation and metastasis of carcinoma although 
      it still remains to be further investigated and confirmed. Emerging data have 
      suggested that TrkB may be a mediator as well as a marker of carcinogenesis and 
      metastasis, therefore TrkB may be used as a valuable target for cancer therapy 
      especially for the metastatic tumors with poor prognosis.
FAU - Han, Lihui
AU  - Han L
AD  - Institute of Immunology, Medical College, Shandong University, Jinan 250012, 
      People's Republic of China.
FAU - Zhang, Zhiyong
AU  - Zhang Z
FAU - Qin, Wen
AU  - Qin W
FAU - Sun, Wensheng
AU  - Sun W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060927
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, trkB)
SB  - IM
MH  - Biomarkers, Tumor/*analysis
MH  - Brain Neoplasms/physiopathology
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Neoplasms/pathology/*physiopathology
MH  - Neuroblastoma/*physiopathology
MH  - Prognosis
MH  - Receptor, trkB/*analysis
EDAT- 2006/09/30 09:00
MHDA- 2007/04/05 09:00
CRDT- 2006/09/30 09:00
PHST- 2006/05/09 00:00 [received]
PHST- 2006/05/11 00:00 [accepted]
PHST- 2006/09/30 09:00 [pubmed]
PHST- 2007/04/05 09:00 [medline]
PHST- 2006/09/30 09:00 [entrez]
AID - S0306-9877(06)00395-1 [pii]
AID - 10.1016/j.mehy.2006.05.038 [doi]
PST - ppublish
SO  - Med Hypotheses. 2007;68(2):407-9. doi: 10.1016/j.mehy.2006.05.038. Epub 2006 Sep 
      27.